Atossa Genetics (NASDAQ:ATOS) Issues Quarterly Earnings Results

Atossa Genetics (NASDAQ:ATOS) announced its quarterly earnings results on Friday. The company reported ($0.95) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.07, FiscalAI reports.

Atossa Genetics Trading Down 2.5%

Shares of Atossa Genetics stock opened at $2.36 on Friday. Atossa Genetics has a 12-month low of $1.70 and a 12-month high of $19.35. The company has a market cap of $20.32 million, a P/E ratio of -0.74 and a beta of 1.29. The company’s fifty day simple moving average is $2.62 and its two-hundred day simple moving average is $4.51.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Rodman & Renshaw began coverage on shares of Atossa Genetics in a research note on Tuesday, July 7th. They set a “buy” rating and a $12.00 price objective for the company. Ascendiant Capital Markets cut their target price on Atossa Genetics from $120.00 to $24.00 and set a “buy” rating on the stock in a research note on Friday, April 10th. Finally, Weiss Ratings downgraded Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Three analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Atossa Genetics presently has a consensus rating of “Hold” and an average price target of $20.33.

Institutional Investors Weigh In On Atossa Genetics

A number of large investors have recently modified their holdings of the stock. Ameriprise Financial Inc. bought a new stake in shares of Atossa Genetics during the 2nd quarter valued at $2,468,000. Renaissance Technologies LLC increased its stake in shares of Atossa Genetics by 33.2% in the 4th quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock worth $1,217,000 after acquiring an additional 514,175 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Atossa Genetics in the 2nd quarter worth about $381,000. Qube Research & Technologies Ltd lifted its position in Atossa Genetics by 357.4% during the 2nd quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock valued at $346,000 after acquiring an additional 325,340 shares during the period. Finally, Vanguard Group Inc. lifted its position in Atossa Genetics by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock valued at $5,270,000 after acquiring an additional 245,717 shares during the period. Institutional investors own 12.74% of the company’s stock.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.